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In recent years a considerable amount of data
have been produced on the activity of the micro-
somal drug metabolizing Systems in the
human fetus [10, 16, 17,18, 19, 21, 26, 29, 32].
They all indicate that the various metabolic
Systems responsible for drug degradation are
already present in the intrauterine life, though
their specific activity is in most cases con-
siderably lower than that of adult Standards.
"In vitro" data, while certainly necessary, do not
provide an exact index of the rate of "in vivo"
metabolism and therefore the Information which
can be derived is not easily applicable to clinical
Problems. In fact drug effects are also determined
by other factors, such äs absorption rate, plasma
protein binding, tissue distribution and ex-
cretion rate. All these factors vary both with age
and physiopathological Status [21, 26]. For this
reason studies and observations on newborn
infants provide further useful Information, which
can eventually be applied to everyday practice.
Most of the data currently available on drug
kinetics and metabolism in the newborn infant
concern antibiotic and sulfonamide compounds
[8, 11, 23, 24, 26, 27, 28] though some obser-
vations have also been carried out with other
drugs [13, 14, 21, 22, 30, 31]. In most cases they
indicate a slower disposition of the drug äs
compared to children.
No data on the metabolic disposition of benzo-
diazepines in the newborn infant have been
available up to now, despite the fact that this
class of drug is widely administered during
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gestation and labor [3, 15], and in the first days
of extrauterine life to control seizures [20]. In the
present report we will describe some observations
we were able to make on premature infants,
full-term infants and children who received
diazepam for therapeutic reasons. In adult
subjects diazepam undergoes metabolic de-
methylation, and hydroxylation, and it is excreted
mainly äs conjugated derivatives [2, 4, 6, 25].
Evidence will be presented that in premature
infants äs well äs in full-term newborns there
is a reduced capability to hydroxylate diazepam
J. Perinat. Mcd. l (1973)
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as well äs a reduced excretion of conjugated
derivatives.
1. Subjects, materials and methods
1.1 Subjects
All patients studied had to receive benzodiazepine to control
seizure disorders or behavioural disturbances. The ob-
servations were carried out on three groups of patients:
— 9 premature infants. 8—81 days old (gestational age
28—34 weeks) 8 full-term infants 4—162 days old,
7 children 3 to 7 years old. In all patients clinical
laboratory tests were within normal limits for liver
functions.
Diazepam (Valium® RÖCHE) was administered i. m. at the
therapeutic dose of 0.3 mg/kg using a HAMILTON-BONADUR
Schweiz microsyringe.
1.2 Blood sampling and urine collection
From 4 prematures and 4 children it was possible to collect
heparinized venous blood samples (l—1.5 ml) at various
times before and after administration (Tab. I).
Fractionated 24 hour urine samples were collected
whenever possible in all the three groups (premature in-
fants, fullterm infants and children). Blood samples were
centrifuged within 30 minutes and the plasma so obtained
kept frozen at 20°C until analyzed for benzodiazepine
content. Similarly samples of urine were frozen after
collection and kept at 20°C until analyzed.
1.3 Chemical analysis
Determination of diazepam (DZ), N-demethyldiazepam
(NDZ) and oxazepam (OX) was carried out on 0.2—0.4 ml
of plasma and on 5—10 ml of urine according to GARATTINI
et al. [5] with some modifications as described below.
1.3.1 Extraction from plasma
0.2—0.4 ml of plasma buffered with l ml of phosphate
buffer (pH 7) was extracted three times with 4ml of
diethyl ether. 10 ml of the organic combined fraction was
then back-extracted with 3 ml of l N HCL The äcqueous
phase was washed twice with 5 ml of diethyl ether and
alkalinized to pH 9—10 with 0.7 ml of 6 N NaOH. The
alkalinized äcqueous fraction was then extracted three times
with 5 ml of diethyl ether and 14 ml of the organic phase
was dried out in a water-bath at 40°C in a finely tapered
test tube. The drug residue was then redissolved in 50 \ of
acetone containing 2-N-benzylamino-5-chloro-benzophe-
none (5 //g/ml) as internal marker, l—2 of 'ttiis solution
was used for GLC determination.
1.3.2 Extraction from urine
5 ml of urine was bufiered with 3 ml of phosphate buffer
(pH 7) and extracted three times with 5 ml of diethyl ether.
12 ml of the organic phase were then processed as des-
cribed for plasma, and the remaining äcqueous phase used
for determination of conjugated compounds.
1.3.3 Extraction of conjugated compounds from
urine
After extraction with ether at pH 7, the äcqueous phase was.
acidified to pH 5 with 0.5 ml of 6 N HC1 and 2.5 ml of
acetate buffer (pH 5) and incubated overnight at 37°C
with 5 103 units of /?-glucuronidase. The urine was
then alkalinized to pH 9—10 with 6 N NaOH and ex-
tracted three times with 5 ml of diethyl ether. 14 ml of the
organic phase were then dried and processed as before.
Determinations of N-Methyloxazepam (MeOX) were
performed on 0.1 ml of plasma and 5 ml of urine according
to the recently described procedure of BELVEDERE et al.
[1]. This procedure is based on the conversion of N-
Methyloxazepam to its TMS derivative and leads to·
improved suisitivity. The identity of the compounds was.
checked by TLC (CH Cl3-Acetone 9:1) and by combined
gaschromatography-mass-spectrometry against known re-
ference Standards.
1.4 Apparatus
A CARLO ERB A Fractovap Model G l, gaschromatograph^
equipped with 63 Mi ECD was used.
Diazepam, N-demethyldiazepam and oxazepam determin-
ations were performed on a glass column 2 m long, 4 mm
i. d., packed with 3% O V 17 on Gaschrom Q (Applied
Science Lab.) operated at the following temperatures:
oven 270°C, injector 280°C, detector 285°C. Carrier gas-
flow (Nitrogen) 40 ml/min.; scavenger gas flow (Nitrogen)'
70 ml/min. N-Methyloxazepam determinations were carried.
out on a glass column l m long, 4 mm i. d., packed as.
before and operated at the following temperatures: oven
220°C, injector 240°C, detector 250°C. Carrier and scaven-
ger gas flow 50 ml/min. An LKB 9000 gaschromatograph-
mass-spectrometer was used for mass analysis.
1.5 Statistical analysis
Owing to the small number o£ blood samples
taken, it was not possible to calculate individuaL
kinetics for the data in Tab. I. However, a
regression analysis on the logarithms o£ the
combined diazepam plasma concentrations showed
that the means at 8, 12, 24 and 48 hours could
be considered to be linearly related for both
premature infants and children.
The slope of the regression line, is proportional
to the average pharmacokinetic elimination
constant, Kel. This Kel may be considered as the
"body elimination rate" (GIBALDI et al. [7]) and
is related to the apparent body half life of the
drug, T1^; the volumeof distribution (Vd) was-
calculated according to GIB ALDI et al. [7],
J. Pcrinat. Med. l (1973)
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A Student's t-test was used to test the significance
of the difference between the slopes o£ the two
regression lines. The results o£ this significance
test extend to cover differences between the body
elimination rates and the apparent body half
lives. Comparisons between means score was made
using Student's t-test.
2. Results
2.1 Plasma levels of diazepam and of its
metabolites in premature infants and
children
As mentioned above in "methods" we were able
to follow up individual plasma levels of
diazepam and of its metabolites after a single
intramuscular administration in 4 premature
infants (cases No. 3, 4, 6, 7) and in 4 children
(cases No. l, 2, 5, 7).
Results summarized in Tab. I show noticeable
individual differences in both groups. The
diazepam plasma levels tended to be higher
and longer lasting in the premature infants
than in the children. Mean values in the pre-
mature infants after 24 and 48 hours were roughly
double those in the children.
Since for ethical reasons it was not possible to
collect enough samples to allow calculation of
individual kinetics, the results in Tab. II are
based on combined data for each of the two
groups. As reported in Tab. II significant dif-
ferences were observed.
Tab. II. Apparent pharmacokinetic constants of diazepam
in permature infants and children.
Prematures
Children
Kel (hr-1)
0.013**
0.038
App T%
54**
18
Vd(l/kg)
1.10
1.99
** = P<0.05 in respect to children group.
The premature group showed a Kel of 0.013
with an apparent plasma half-life of 54 hours,
while the children had a Kel of 0.038 and an
apparent plasma half-life of 18 hours (P < 0.05
for this difference). Diffqqences were also present
in the volume of distribution.
With regard to the diazepam metabolites no N-
methyloxazepam or oxazepam could be detected
in plasma of either group. N-demethyldiazepam,
on the contrary, was f ound in measurable amounts
both in prematures and children. Even so,
appreciable differences were observed.
While in all the four children studied N-de-
methyl diazepam was already present in meas-
urable amounts l hour after drug administration,
in the premature infants the compound was
measurable only after 8 hours in 3 out of 4 cases.
These data suggest a slower demethylation
process in premature infants. It is also inter-
esting that while for the children in 3 out of 4
cases the N-demethyldiazepäm levels tended to
decline after 24 hours, for the premature group
in 3 out of 4 cases the N-demethyldiazepam levels
were still increasing after 48 hours. These data
suggest a reduced breakdown of the demethyl-
ated metabolite.
2.2 24-hour urinary excretion of diazepam
and of its metabolites in premature in-
fants and children
The 24-hour urinary excretion of diazepam and
its metabolites was followed up in 7 premature
infants (cases No. l, 2, 5, 6, 7, 8, 9), 8 füll term
infants (cases No. l, 2, 3, 4, 5, 6, 7, 8), and 5
children (cases No. 2, 3, 4, ^5, 6). The 24-hour
urinary excretion of unconjugated benzodia-
zepines (Diazepam and N-demethyldiazepam)
was found to be very small (Tab. III) and no
Tab. III. Mean values of the 24 hour urinary excretion of
unconjugated benzodiazepines in premature infants,
fullterm infants and children fpllowing an i. m. admi-
nistration of 0.3 mg/kg of diazepam.
Unconjugated Benzodiazepines
DZ NDZ Total
Premature
Fullterm
Children
0.053
±0.010
0.052
±0.022
0.017
±0.006
0,057
±0.020
0.174
±0.048
0.054
±0.012
0.110
±0.022
0.226
±0.053
0.071
±0.013
Values are expressed äs % of the administered dose.
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significant differences were noticed among
the three groups.
Analysis of ethereal extracts of urine incubated
with ß-glucuronidase showed the following
three compounds to be present: N-demethyl-
diazepam, N-methyloxafcepam and oxazepam.
There were significant difFerences between the
three age groups (Tab. IV).
Tab. IV. Mean values of the 24 hour urinary excretion of
conjugated benzodiazepines in permature infants, füll term
infants and children following an i. m. administration of
0.3 mg/kg of diazepam.
Total conjugated Benzodiazepines
Premature
Fullterm
Children
0.987±0.434
1.418;t0.453
4.377± 1-007
(P<0.01)*
(P<0.05)*
Values are expressed äs % of the administered dose
* = with respect to children.
The total amount of benzodiazepine excreted äs
conjugated compounds in the first 24 hour s
following drug administration was higher in
children than in full-term infants (P < 0.05)
or in premature infants (P < 0.01).
This picture becomes more interesting when we
consider the single metabolic products and their
ratios. In fact, äs reported in Tab. V, although
N-demethyldiazepam was present in equivalent
amounts in all the groups, marked difFerences
were observed with regard to the hydroxylated
metabolites (N-methyloxazepam and oxazepam).
In the premature group no hydroxylated com-
pounds were detectable even in the 81 day-old
subject (case 9). In the full-term group, hy-
droxylated compounds were absent or present in
unmeasurable amounts up to 10 days of age,
while they were constantly present in subjects
over 2—3 weeks of age.
Tab. V. 24 hour urinary excretion of diazepam metabolites in premature infants, füll term infants and children after an
i. m. administration of 0.3 mg/kg of diazepam.
Case
i
4->
i&
4H
£
1
d<u
23
1
2
5
6
7
8
9
1
2
3
4
5
6
7
8
2
3
4
5
6
8
15
17
13
8
21
81
4
4
10
18
30
96
143
162
4
5
5
6
7
Age*
d
d
d
d
d
d
d
d.
d.
d.
d.
d.
d.
d.
d.
y.
y·
y.
y.
y·
(28w)
(32w)
(32w)
(34w)
(34w)
(34w)
(32w)
B.W.
[kg]
2.1
2.1
2.2
2.3
2.2
2.1
2.9
3.1
3.2
3.3
3.4
3.1
4.2
5.1
4.8
16.1
20.0
14.0
17.5
18.0
24h
Urine
[ml]
315
150
101
170
238
240
188
113
216
185
225
147
130
285
244
215
410
615
500
840
NDZ MeOX
[% of administered
0.96
0.36
0.19
0.74
0.54
0.67
3.52
0.23
0.46
0.86
1.46
0.38
1.50
0.50
0.75
0.99
0.81
1.87
2.69
0.98
n.d.
n.d.
n. d.
n.d.
n. d.
n.d.
n.d.
traces
n.d.
traces
0.48
0.12
2.52
0.40
0.98
0.70
1.52
2.12
1.14
0.86
OX
dose]
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.
n. d.
n.d.
n.d.
n.d.
traces
0.07
0.01
0.01
0.57
2.00
0.53
1.23
4.34
0.76
Total
conjugated
[% of
admi-
nistered
dose]
0.96
0.36
0.19
0.74
0.54
0.67
3.52
0.23
0.46
0.86
1.94
0.58
4.06
0.92
2.30
3.71
2.90
4.61
8.23
2.69
* = For premature infants the gestational age at birth is reported in parentheses.
n. d. = not detectable. The sensitivity of the method allows determinations of urine concentrations äs low äs 0.15 ng/ml
for MeOX and 0.30 ng/ml for OX.
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Tab. VI. Ratio* between hydroxylated and non-hydroxylated benzodiazepines present in the 24 hour urine of premature
infants, fullterm infants and children after diazepam administration (0.3 mg/kg i. m.)
Premature infants Fullterm infants Children
Gest. age Ratio
[weeks]
28 —
32 —
32 —
34 —
34 —
34 —
32 —
[Age days]
4
4
10
18
30
96
143
162
Ratio
—
—
—0.24
0.40
1.27
0.74
1.73
[Age years]
4
5
5
6
7
Ratio
2.67
2.41
2.66
1.99
1.52
= (MOX) + (ΟΧ)
(DZ) + (NDZ) in 24 hour urine.
7prematures f u l l t e r m infqnts 5 c h i l d r e n
'2.0-
l
1.5- τ
2 1.0
8-21 daysold 4-162daysold 3.5-8 years old
(28-34 weeks
- gestage)
- -i
-
 J1 fi i-L ιϊι J.
NDDZ MOX OX NDDZ MOX OX NDDZ MOX OX
Fig. 1. 24 hour urinary excretion of diazepam meta-
bolites after a single i. m. administration of 0.3 mg/kg of
diazepam
However, mean values were lower when com-
pared to the children (Fig. 1). The difference was
more marked for oxazepam than for N-methyl-
oxazepam. If we consider the ratios between the
hydroxylated derivatives and the non-hydroxyl-
ated ones, we can see (Tab. VI) that only in the
5 month-old infant is the ratio of the same
magnitude s that observed in fully grown
children.
3. Discussion
After administration of a single pro kilo dose
of the drug, premature infants tended to have
higher and more persistent plasma levels of
diazepam in comparison to the children. The
apparent plasma disappearance rate was signi-
ficantly prolonged in the premature group
suggesting a reduced capability of the processes
responsible for molecule breakdown and eli-
mination. Other factors may however play an
important role in determining this phenomenon.
Diazepam is kiiown to accumulate in con-
siderable amounts in the adipose tissue of
animals and humans [6, 12]. A different binding
of diazepam to various tissue components or a
reduced amount of adipose tissue could in part
explain the higher levels of diazepam observed
in premature infants. In fact a considerable
difference in distribution of volume was observed
in our cases. The rate of formation of N-de-
methyldiazepam was slower in prematures than
in children suggesting that the total capacity of
the demethylating System is comparatively re-
duced in the first group.
Furthermore that the tendency to accumulate N-
demethyldiazepam with high »levels persists even
after 48 hours suggests that hydroxylation
processes are likewise inefficient in the
premature. This hypothesis is further sustained
• by the urinary data. No hydroxylated compounds
could in fact be detected in the urine of premature
infants and the same was observed in full-term
infants less than two weeks old. The total con-
jugated benzodiazepines present in the 24 hour
urine were also lower in premature and f ll term
infants than in children. Other authors [9, 21]
have described the presence of hydroxylated
compounds in the urine of newborns after drug
administration to the mother.r However no
attempt was really made to clarify whether the
hydroxylated compounds were derived from the
mother or were inherent in the newborn metab-
olism.
J. Perinat. Med. l (1973)
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A reduced drug metabolizing activity in the
premature and newborn is further supported
by preliminary observations [26] in which
diazepam and its metabolites were followed up
in newborns whose mothers had been exposed to
benzodiazepine treatment before the delivery.
It was seen that both diazepam and N-de-
methyldiafcepam crossed the placenta and
both accumulated in the fetus. The plasma
concentrations of diazepam and N-demethyl-
diazepam were quite constant during the first
48—72 hours of extra-uterine life, suggesting a
reduced capacity in the newborn to further
metabolize the drugs.
In conclusion it appears from our data that
newborn infants, both premature and füll
term, have a limited capacity for metabolizing
and excreting drugs. It also seems likely that
the degree of limitation of the various drug
Summary
Benzodiazepines are often used during labor, and they are
also frequently administered to newborns in cases of
seizure. In adults this class of drug requires an extensive
metabolization in order to be eliminated.
The physiological elimination of diazepam admi-
nistered at the dose of 0.3 mg/kg by intramuscular route
(Tab. I), was followed up in three groups of subjects
{premature infants, full-term infants and children).
Plasma levels of diazepam (DZ) and of its major metabolite
N-demethyldiazepam (NDZ) could be followed up for
48 hours after drug administration in 4 premature infants
and 4 children.
24 hour urinary excretion of DZ, NDZ, N-Methyl-
oxazepam (MeOX) and Oxazepam (OX) was followed up
in 7 premature infants, 8 füll term infants and 5 children.
Determination of benzodiazepine compounds both in
plasma and urine, was performed, after etheral extraction,
by GLC-ECD. In the urine samples free and cönjugated
compounds were measured (Tab. HD.
The apparent disappearance rate of diazepam plasma was
significantly reduced (P < 0.05) in premature infants
(Tx/2 = 58 hrs) when compared to that of the children
metabolizing Systems is not uniform, and different
results may also be obtained with other Substrates.
From a practical point of view, a limited metab-
olizing and excreting activity implies a longer
persistence of pharmacologically active substances
in the neonatal body fluids and tissues, and
consequently prolonged pharmacological effects.
The clinical implications of this phenomenon
are almost completely unknown. Although our
findings cannot establish the optimal dosage
regimen of diazepam, they suggest that the drug
should be used in premature and füll term
infants at lower doses than in children. More
data are needed on the metabolism of drugs in
newborns and infants äs the necessary premise to
a more integrated approach, both pharmacological
and clinical, to the problem of drug dosage in
newborn infants.
The rate of formation of N-demethyldiazepam was
slower in prematures than in children.
A difference in the distribution of volume was also noticed.
The urinary data further supported reduced DZ eli-
mination in the premature infants and fullterm infants.
No hydroxylated derivatives (MeOX and OX) were in
fact found in the urine of premature infants nor in the
urine of full-term infants up of 10 days of age.
On the contrary the hydroxylated compounds (MeOX and
OX) represented the major portion of diazepam meta-
bolites present in the urine of children.
The data indicate that in the newborn (either premature
or füll term) the physiological elimination of diazepam
is markedly reduced when compared to children.
This is probably du? to a limited capacity to form N-
demethylated and hydroxylated derivatives which are
subsequently excreted äs such or äs cönjugated compounds.
A prolonged persistence of diazepam and of its N-
demethylderivative (which still retains pnarmacological
activity) in the biological fluids and tissues has to be taken
into account when this drug is administered to newborns.
= 18 hrs).
Keywords: Diazepam, physiological elimination, metabolism, premature infants, füll term infants, children, plasma levels,
urinary excrstion.
Zusammenfassung
Diazepam-Ausscheidung bei Frühgeborenen und reifen
Neugeborenen sowie älteren Säuglingen
Benzodiazepine wercfen oft während der Geburt verab-
reicht und auch häufig Neugeborenen gegeben, wenn sie
Krampfanfälle bekommen. Bei Erwachsenen benötigt
dieses Medikament einen komplizierten Abbau, bevor
es ausgeschieden werden kann.
Der Abbau des Diazepam, intramuskulär injiziert in
einer Menge von 0.3 mg/kg, wurde verfolgt in drei
Gruppen (Frühgeborene, Termingeborene und ältere
Säuglinge). Die Konzentration des Diazepam und seines
wichtigsten Stoffwechselprodukts, N-Demethyldiazepam
(NDZ) im Plasma wurde während 48 Stunden gemessen
bei 4 Frühgeborenen und 4 Säuglingen. Die Ausscheidung
von DZ, NDZ, N-Methyloxazepam (MeOX) und Oxa-
J. Pcrinat. Med. l (1973) 10*
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zepam (OX) wurde im Urin 7 Frühgeborener, 8 reifer
Neugeborener und 5 Kinder 24 Stunden lang verfolgt.
Nach Ätherextraktion mit GLC-ECD wurden die Benzo-
diazepin-Verbindungen im Plasma und Urin bestimmt. Im
Urin haben wir auch die freien und konjugierten Sub-
stanzen gemessen.
Unsere Untersuchungen ergaben, daß Diazepam wesent-
lich langsamer aus dem Plasma verschwindet (P <
0.05, wenn das Kind zu früh geboren wurde ( /2 =
58 Stunden bei Frühgeborenen und Tx/2 = 18 Stunden für
ältere Kinder). N-Demethyl diazepam wurde entsprechend
langsamer produziert in diesen Frühgeborenen. Ein Unter-
schied in der Menge der Verteilung konnte auch be-
obachtet werden. Die Ergebnisse der Urinuntersuchung
unterstützten auch die Beobachtung einer verminderten
DZ-Ausscheidung bei Frühgeborenen und Termingebore-
Schlüsselwörter: Diazepam, Ausscheidung, Stoffwechsel, Frühgeborene, Reife Neugeborene, Säuglinge, Plasma-Kon-
zentration, Urinausscheidung.
nen. In der Tat wurden keinerlei Hydroxylderivate
(MeOX und OX) im Urin frühgeborener oder andeter
Neugeborener vor dem zehnten Lebenstag gefunden.
Andrerseits waren diese Hydroxylderivate dfe Haupt-
portion der DZ-Stoffwechselprodukte im Urin älterer
Säuglinge.
Diese Ergebnisse zeigen, daß beim Neugeborenen die
physiologische Ausscheidung des Diazepam wesentlich
reduziert ist. Dies stellt wahrscheinlich eine verminderte
Fähigkeit dar, N-Demethyl und Hydroxylderivate zu
bilden, die nachher als solche oder als konjugierte Sub-
stanzen ausgeschieden werden. Diazepam und sein N-
Demethylderivat bleiben daher länger in den biologischen
Flüssigkeiten und Geweben, wo sie weiterhin ihre pharma-
kologische Tätigkeit ausüben.
OElesume
Metabolisme du Diazepam chez le nouveau-ne pre-
mature et ä terme et chez l'enfant
Les benzodiazepines sont souvent employees au cours du
travail, et elles sont aussi frequemment administrees au
nouveau-ne en cas de convulsions. Chez l'adulte, ce type de
produit doit subir des modifications metaboliques im-
portantes pour etre elimine.
Le metabolisme du diazepam, administre ä la dose de
0,3 mg/kg par voie intra-musculaire, a ete etudie pour
trois groupes de sujets (prematures, nouveau-nes ä
terme et enfants). Le taux de diazepam (DZ) plas-
matique et de son principal metabolite N-demethyl-
diazepam (NDZ) a pu etre suivi pendant 48 heures apres
l'administration du medicament chez quatre prematures et
quatre enfants.
L'excretion urinaire de 24 heures de DZ, NDZ, N-
Methyloxazepam (MeOX) et Oxazepam (OX) a ete
suivie chez 7 prematures, 8 nouveau-nes ä terme et 5
enfants.
La mesure des composes benzodiazepiniques dans le
plasma et dans l'urine a ete realisee, apres extraction par
l'ether, par «GLC-ECD». Dans les echantillons d'urine on
a mesure les composants libres et conjuges. La vitesse de
disparition apparente du diazepam plasmatique etait
reduite de fac/m significative (P < 0.05) chez les
prematures (T1/2 = 58 h) par rapport a celle des enfants
(TV2 = 18h).
La vitesse de formation du N-demethyldiazepam
etait chez les prematures inferieure ä celle des enfants.
On a aussi note une difference dans le volume de distri-
bution. Les resultats des dosages urinäires etaient tres en
faveur d'une diminutibn d'excretion de DZ chez les
prematures et chez les nouveau-nes a terme. On n'a pas
mis en evidence de derives hydroxyles (MeOX et OX) dans
les urines des prematures ni dans les urines des enfants nes ä
terme jusqu'ä 10 jours d'äge.
Au contraire, les composes hydroxyles (MeOX et OX)
representaient la majeure partie des mdtabolites presents
dans l'urine des enfants. Ces resultats indiquent que chez
le nouveau-ne le metabolisme du diazepam est nette-
ment reduit, par rapport ä celui de l'enfant.
Ceci est probablement du a la capacite limitee de former
des derives N-demethyles et hydroxyles qui sont
ensuite excretes sous cette forme ou sous forme conjuguee.
La persistance prolongee de diazepam et de ses derives
N-demethyles (qui gardent une activite pharmacologique)
dans les liquides biologiques et les tissus, doit etre prise en
consideration lorsqu'on administre cette drogue aux
nouveau-nes.
Mots-cles: Diazepam, metabolisme, premature, nouveau-ne a terme, enfant, taux plasmatique, excretion urinaire.
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